Breaking News

Putin, Poroshenko Agree on Cease-Fire in Ukraine
Tweet TWEET

Amarin Announces Additional Vascepa(R) (icosapent ethyl) Supplier

Amarin Announces Additional Vascepa(R) (icosapent ethyl) Supplier

Fourth API Supplier Further Solidifies Worldwide Supply Chain

BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 11, 2012 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
development of therapeutics to improve cardiovascular health, today announced
the addition of an exclusive consortium of companies led by Slanmhor
Pharmaceutical, Inc. (Slanmhor) to its planned active pharmaceutical
ingredient (API) global supply chain for Vascepa® (icosapent ethyl) capsules.
Slanmhor was spun-out from Ocean Nutrition Canada (ONC) prior to the May 2012
acquisition of ONC by Royal DSM N.V. (DSM), a global leader in life sciences
and materials sciences. Amarin now has a total of four API suppliers for
Vascepa API for Amarin to utilize to support the global commercialization of
Vascepa, subject to appropriate regulatory approvals.

Slanmhor, based in Halifax, Nova Scotia, Canada, is led by CEO Robert Orr, a
pioneer and industry leader in the omega-3 manufacturing industry and the
former Chairman and CEO of ONC, the world's largest supplier of concentrated
omega-3 fatty acid products. In producing API for Amarin, Slanmhor, through
exclusive agreements, is collaborating with DSM/ONC for the supply of
intermediate omega-3 oil, and Novasep, a global leader in purification
technologies and API manufacturing. The Slanmhor/DSM/Novasep consortium offers
one of the most well established omega-3 current good manufacturing practice
(cGMP) API manufacturing solutions globally and further solidifies Amarin's
capability to reliably source Vascepa.

"We have found very few companies with the technical ability to produce
Vascepa to our unique specifications. The addition of this exclusive Slanmhor
consortium rounds out our global diversity and expands our potential capacity
to meet the anticipated market demand for Vascepa," said Joseph Zakrzewski,
Chairman and Chief Executive Officer of Amarin. "Pooling the resources of four
of the world's leading omega-3 API manufacturers supports the commercial
potential of Vascepa by providing for additional scalability and reliability
to Amarin's supply chain."

Amarin's current plan is to launch Vascepa based on product produced by its
existing API supplier, Nisshin Pharma. Amarin has agreed to a protocol with
FDA for the qualification of additional API suppliers. Amarin's plan is for
Slanmhor, along with BASF and Chemport, to complete all necessary
qualification steps to facilitate the submission of supplemental New Drug
Applications that seek approval for Amarin's new suppliers to manufacture
Vascepa for use in the United States. 

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids.Vascepa^® (icosapent
ethyl),Amarin'sfirstFDAapproved product, is a patented, ultra pure omega-3
fatty acid comprising not less than 96%EPA. For more information about
Vascepa visit www.vascepa.com. For more information about Amarin visit
www.amarincorp.com.

The Amarin Corporation plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13817

About DSM – Bright Science. Brighter Living.™

Royal DSM is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in Life Sciences and Materials
Sciences DSM is driving economic prosperity, environmental progress and social
advances to create sustainable value for all stakeholders. DSM delivers
innovative solutions that nourish, protect and improve performance in global
markets such as food and dietary supplements, personal care, feed,
pharmaceuticals, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials.
DSM's 22,000 employees deliver annual net sales of around €9 billion. The
company is listed on NYSE Euronext. More information can be found
atwww.dsm.com

About Novasep

Novasep, headquartered in Pompey, France, is a global provider of
cost-effective and sustainable solutions to produce active molecules at the
required purity. Novasep's unique offering includes process development
services; purification equipment and turnkey processes; contract manufacturing
services; and complex active molecules to serve pharmaceutical;
biopharmaceutical; agrochemical; fine chemical; food and functional
ingredients; and bio-industries.Novasep employs 1,200 people and has a global
footprint including numerous FDA inspected API manufacturing plants,
biopharmaceutical production sites and equipment manufacturing facilities.

About Slanmhor

Slanmhor Pharmaceutical, Inc. is a Canadian corporation with headquarters in
Halifax, Nova Scotia. Slanmhor specializes in the manufacture and supply chain
management of omega-3 based Active Pharmaceutical Ingredients. Slanmhor is a
wholly-owned subsidiary of Clearwater Fine Foods, Inc., a Canadian based
investment holding company with principal holdings that also include seafood
harvesting, processing and telecommunications.

Forward-looking statements

This press release contains forward-looking statements, including statements
about the manufacturing capacity and qualification of Vascepa suppliers and
planned regulatory approvals and timing related thereto. These forward-looking
statements are not promises or guarantees and involve substantial risks and
uncertainties. Among the factors that could cause actual results to differ
materially from those described or projected herein include the following:
uncertainties associated generally with reliance on third parties,
manufacturing capabilities, supply of pharmaceutical product and related
regulatory approvals. A further list and description of these risks,
uncertainties and other risks associated with an investment in Amarin can be
found in Amarin's filings with the U.S. Securities and Exchange Commission,
including its most recent Quarterly Report on Form 10-Q.Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.

CONTACT: Amarin contact information:
         Stephen D. Schultz
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.